NGF and osteoarthritis: Although tanezumab has been tested as a potential analgesic for patients with osteoarthritis, it did not secure FDA approval due to safety concerns linking use of NGF inhibitors to accelerated joint damage, and publication of NICE guidelines for the use of tanezumab to treat moderate-to-severe osteoarthritis pain is currently suspended.